Abstract
EVIDENCE has accumulated which stresses the importance of lymphokines in cell-mediated immunity both in vivo and in vitro1. But, the processes leading to release of lymphokines by antigen-activated lymphocytes, the mode of action of these lymphokines and their exact role in cell-mediated immunity are still not well defined. It has, however, been recognised that in vitro activation of immune lymphocytes by soluble antigens is macrophage dependent and that this activation is under the control of gene products of the major histocompatibility complex (H–2 in the mouse)2. Using a Moloney murine sarcoma virus (MSV)-induced tumour system, we have shown, in agreement with reports of some other systems3,4, that immune T lymphocytes required macrophages for migration inhibition factor (MIF) production and, in addition, only histocompatible macrophages could assist immune T lymphocytes for MIF release after stimulation with soluble tumour-associated antigens5. We report here that gene products of the H–2 complex regulated the macrophage-immune lymphocyte interaction for MIF release when soluble tumour extracts were used as the source of antigen. In contrast, when intact tumour cells were used as the source of antigen, a macrophage requirement was not detectable. Moreover, the direct lymphocyte-tumour cell interaction for MIF release was not under H–2 restriction, since allogenic as well as syngeneic tumour cells could activate MIF release from immune lymphocytes. These findings suggest the existence of at least two different pathways for MIF production, reflecting perhaps the activation of two distinct sub-populations of T lymphocytes or the activation of T lymphocytes at two different stages of differentiation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
David, J. & David, R. Prog. Allergy 16, 300 (1972).
Katz, D. H. & Benacerraf, B. The Role of Products of the Histocompatibility Gene Complex in Immune Responses (Academic, New York, 1976).
Nelson, R. D. & Len, R. W. J. Immun. 114, 606–609 (1975).
Wahl, S. M., Wilton, J. M., Rosenstreich, D. L. & Oppenheim, J. G. J. Immun. 114, 1296–1301 (1975).
Landolfo, S., Herberman, R. B. & Holden, H. T. J. Immun. 118, 1244–1248 (1977).
Kirchner, H., Chused, T. M., Herberman, R. B., Holden, H. T. & Lavrin, D. H. J. exp. Med. 139, 1473–1487 (1974).
Ly, I. A. & Mishell, R. I. J. Immun. Meth. 5, 239–247 (1974).
Herberman, R. B. et al. J. natn. Cancer Inst. 53, 1103–1111 (1974).
Landolfo, S., Herberman, R. B. & Holden, H. T. J. natn. Cancer Inst. (in the press).
Yam, L. T., Li, C. Y. & Crosby, W. H. Am. J. clin. Path. 55, 283–290 (1971).
Gorski, A. J., DuPont, B., Hansen, J. A. & Good, R. A. J. Immun. 117, 865–870 (1976).
Holden, H. T., Landolfo, S. & Herberman, R. B. Transplant. Proc. 9, 1149 (1977).
Holden, H. T. & Herberman, R. B. Nature 268, 250–252 (1977).
Plata, F., Jongeneel, V., Cerottini, J.-C. & Brunner, K. T. Eur. J. Immun. 6, 823–829 (1976).
Thomas, W. D. & Shevach, E. M. J. exp. Med. 114, 1263–1275 (1976).
McCoy, J. L., Fefer, A. & Glynn, J. P. Cancer Res. 27, 1743–1748 (1968).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
LANDOLFO, S., HERBERMAN, R. & HOLDEN, H. Two mechanisms of migration inhibition factor induction by tumour antigens. Nature 270, 62–64 (1977). https://doi.org/10.1038/270062a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/270062a0
This article is cited by
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.